"Insights from Industry" is a dynamic series of interviews at the cutting edge of the life sciences industry.
Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible
insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.
There are two main challenges and both relate to manufacturing. The first one is to make sure you can manufacture therapies with reasonable costs and the second one is to make sure that you can balance the capacity you need with the demands.
This test, which we have branded SelectMDx for Prostate Cancer, came with the acquisition of a company in the Netherlands called NovioGendix. They developed a prototype assay, so they did most of the heavy lifting in terms of discovering the two specific biomarkers that are currently in the product. These biomarkers are tuned towards the detection of what I call clinically significant prostate cancer.
The first thing is, to always remember that we're dealing with a living drug, cells, which are very sensitive to environmental conditions, such as temperature and humidity etc. All of those things can impact on the viability of the drug and its effectiveness.
The pharma and biotech industry continues to struggle to make progress with gender diversity. A recent Credit Suisse report shows that management diversity, as defined by percentage of women in senior management roles, has decreased globally from 18.9 percent in 2014 to 15.5 percent in 2016.
Australia is an acknowledged world leader in the medical technology, biotechnology and pharmaceutical (MTP) sector due to its vibrant ecosystem of start-ups and established companies and thriving research environment.
Organoids are bits of tissue grown in vitro, in a near-physiological 3D setting. The particularity consists in the fact that organoids retain features of the patient they are derived from, even when cultured outside of the human body. This is very different from what traditional, conventional cell culture has been able to do over the past 50 years or so.
An interview with Gilberto Dalmaso, discussing the different grades of pharmaceutical cleanrooms and the production of high level compounds under aseptic conditions.
Solvent removal covers a broad range of applications where it is necessary to remove or concentrate a solvent from a solution.
In this interview, Jay Flatley, Executive Chairman of Illumina, gives an introduction to Illumina and the next generation genomics tools they provide.
In this interview Penny Owen, Interim Executive Chair, Life Sciences Hub Wales, describes recent advances in Life Sciences in Wales, and if we are likely to see changes in this due to Brexit.
An interview with Dr. Chase Spurlock, CEO, discussing IQuity's research into IncRNAs and how they are linked to autoimmue diseases.
In this interview, Alison Wake from Genevac, discusses the use of centrifugal concentraters in biological research, and the miVac range provided by Genevac.
An interview with Jean Fallacara, CEO, discussing how Z-SC1 help to ensure safe sample storage at ultra-low temperatures, conducted by James Ives, MPsych
In this interview, Dr Harmut Schafer introduces the work being done at the Phenome Center in Birmingham, on metabolic phenotyping using NMR.
An interview with Ian Holland, discussing the differences in microscope cameras and how to determine which one is most suitable for specific pathology applications.
Patricia Beaune provides an overview of the honey industry and explains the techniques that are currently being used to detect and identify counterfeit honey products.
In this interview, Peter Banks discusses the advantages of quantitative microscopy, and provides advice on selecting a microscope for this application.
News-Medical speaks to Dr. Quentin Barraud about his work on spinal cord repair and how he uses the CLARITY technique in his research.
Andrew Jones discusses the importance of quality control in NGS and the effect that a poorly followed protocol can have on experimental results.